Make DUPIXENT
Your First-Choice
Biologic

#1 Biologic Prescribed by
Allergists6

#1 Biologic Prescribed by
Pulmonologists for
Asthma Patients7

Prescribed to >99,900 asthma patients by >15,200 healthcare providers in the United States8,b,c

bLH Patient View; data through February 2023.

cNew adult and pediatric patients aged 6 years and older with moderate-to-severe eosinophilic or OCS-dependent asthma.

DUPIXENT is the Only Biologic that Combines the Ability to:

Target
More Than One

Source of
Type 2 Inflammation by
Specifically Inhibiting
IL-4 and IL-13 Signaling

  • IL-4 and IL-13 are two of the key drivers of local and systemic type 2 inflammation1-5,a

aThe mechanism of dupilumab action has not been definitively established.1

Explore
the MoA

Treat
More Than One

Asthma
Patient Type

  • Specifically indicated for OCS-dependent asthma patients and for moderate-to-severe asthma patients with eosinophilic phenotype1
  • Markers of type 2 inflammation: proven data in indicated patients with ≥1 of the following9,10
    • EOS ≥150 cells/µL
    • IgE ≥30 IU/mLd
    • FeNO ≥20 ppb
EXPLORE APPROPRIATE
PATIENT TYPES

Control
More Than One

Measure of
Uncontrolled Asthma

  • Exacerbation reduction: Up to 81% significant reduction in annualized rate of severe exacerbations through Week 241,e
  • Lung function improvement: Rapid FEV1 improvement at Week 2f and sustained through Week 521,11,g
  • OCS reduction/elimination: 86% of patients reduced or eliminated their OCS dose at Week 2412,h
Explore the Efficacy
and Safety Data

dPlus ≥1 positive perennial-aeroallergen-specific IgE ≥0.35 kU/L at baseline.10

eWith DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (DRI12544, EOS ≥300 cells/µL, secondary endpoint).1

f~72% of the total FEV1 improvement was seen at Week 2 with DUPIXENT 200 mg Q2W + SOC (n=264) (QUEST, EOS ≥300 cells/µL, secondary endpoint).1,11

g470 mL sustained breathing relief was seen at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint).1

hWith DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (VENTURE, ITT population).12

EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ITT, intention-to-treat; OCS, oral corticosteroid; Q2W, once every 2 weeks, SOC, standard of care.

Mechanism of Action
(MOA)

Only DUPIXENT targets both IL-4 and IL-13 signaling, two of the key drivers of local and systemic type 2 inflammation1-5,a

EXPLORE THE MOA

aThe mechanism of dupilumab action has not been definitively established.1

Multiple Dosage and
Administration Options

Offer your patients 6 years and older flexible administration: at home or in office1

SEE DOSAGE AND ADMINISTRATION

Safety
Data

View safety data across asthma
clinical trials

SEE safety DATA

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN HOW WE CAN HELP

DUPIXENT MyWay
ENROLLMENT FORMS
FOR ALLERGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ENT SPECIALISTS/
PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form

99%

of OCS-dependent asthma patients who are commercially insured required no biomarker testing13

~98%

of commercially insured patients nationally are covered for DUPIXENT13,i,j

iMMIT Lives as of March 2023.

jCoverage varies by type and plan.

Check formulary status in your area

See insurance coverage status, prior authorization, and step edit information for DUPIXENT.

Look up coverage
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your
product-related questions.
CONTACT A REP